Emerging therapeutics for the treatment of diabetic nephropathy

Bioorganic and Medicinal Chemistry Letters

Volumn 26, Issue 18, 2016, Pages 4394-4402

  Brenneman, Jehrod ^a   Hill, Jon ^a   Pullen, Steve ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Diabetic nephropathy; Fibrosis; Inflammation; Kidney disease; Therapeutics

Indexed keywords

COMPLICATION; DIABETIC NEPHROPATHIES; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS;

EID: 84983027914     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.07.079     Document Type: Review

References (110)

1. 1 Venkatachalam, M.A., Weinberg, J.M., Kriz, W., Bidanai, A.K., J. Am. Soc. Nephrol., 26, 2015, 1765.
2. 2 G.M.A.C.O.D. Collaborators. Lancet, 385, 2014, 117.
3. 3 Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Yee-Moon Wang, A., Yang, C.-W., Lancet, 382, 2013, 260.
4. 4 Boyle, J.P., Thompson, T.J., Gregg, E.W., Barker, L.E., Williamson, D.F., Popul. Health Metr., 8, 2010, 1.
5. 5 Remuzzi, G., Benigni, A., Finkelstein, F.O., Grunfeld, J.-P., Joly, D., Katz, I., Liu, Z.-H., Miyata, T., Perico, N., Rodriguez-Iturbe, B., Antiga, L., Schaefer, F., Schieppati, A., Schrier, R.W., Tonelli, M., Lancet, 382, 2013, 353.
6. 6 Ramos, A.M., Gonzalez-Guerrero, C., Sanz, A., Sanchez-Nino, M.D., Rodriguez-Osorio, L., Martin-Cleary, C., Fernandez-Fernandez, B., Ruiz-Ortega, M., Ortiz, A., Expert Opin. Drug Discov., 10, 2015, 541.
7. 7 Stefoni, S., Cianciolo, G., Baraldi, O., Iorio, M., Angeline, M.L., Expert Opin. Emerg. Drugs, 19, 2014, 183.
8. 8 Cernaro, V., Trifiro, G., Lorenzano, G., Lucisano, S., Buemi, M., Santoro, D., Expert Opin. Investig. Drugs, 23, 2014, 693.
9. 9 Nanthakumar, C.B., Hatley, R.J.D., Lemma, S., Gauldie, J., Marshall, R.P., Macdonald, S.J.F., Nat. Rev. Drug Disc., 14, 2015, 693.
10. 10 Johnson, S.A., Spurney, R.F., Am. J. Physiol. Renal Physiol., 309, 2015, F807.
11. 11 Munoz-Felix, J.M., Gonzalez-Nunez, M., Martinez-Salgado, C., Lopez-Novoa, J.M., Pharmacol. Ther., 156, 2015, 44.
12. 12 Kok, H.M., Falke, L.L., Goldshmeding, R., Nguyen, T.Q., Nat. Rev. Nephrol., 10, 2014, 700.
13. 13 Impellizzeri, D., Esposito, E., Attley, J., Cuzzocrea, S., Pharmacol. Res., 81, 2014, 91.
14. 14 Machowska, A., Carrero, J.J., Lindholm, B., Stenvinkel, P., Transl. Res., 167, 2016, 204.
15. 15 El-Haddad, B., Reule, S., Drawz, P.E., Curr. Diab. Rep., 15, 2015, 70.
16. 16 Perez-Gomez, M.V., Sanchez-Nino, M.D., Sanz, A.B., Martin-Cleary, C., Ruiz-Ortega, M., Egido, J., Navarro-Gonzalez, J.F., Ortiz, A., Fernandez-Fernandez, B.J., Clin. Med., 4, 2015, 1325.
17. 17 Tampe, D., Zeisberg, M., Nat. Rev. Nephrol., 10, 2014, 226.
18. 18 Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P., N. Engl. J. Med., 345, 2001, 870.
19. 19 Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I., N. Engl. J. Med., 345, 2001, 851.
20. 20 Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D., N. Engl. J. Med., 329, 1993, 1456.
21. 21 Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S., N. Engl. J. Med., 345, 2001, 861.
22. 22 Ruilope, L.M., Curr. Med. Res. Opin., 24, 2008, 1285.
23. 23 Motlitch, M.E., DeFronzo, R.A., Franz, M.J., Keane, W.F., Mogensen, C.E., Parving, H.H., Steffes, M.W., Diabetes Care, 27, 2004, S79.
24. 24 Dhaun, N., Goddard, J., Webb, D.J., J. Am. Soc. Nephrol., 17, 2006, 943.
25. 25 Czopek, A., Moorhouse, R., Webb, D.J., Dhaun, N., Am. J. Physiol. Regul. Integr. Comp. Physiol., 310, 2016, R388.
26. 26 Culshaw, G.J., MacIntyre, I.M., Dhaun, N., Webb, D.J., Semin. Nephrol., 35, 2015, 176.
27. 27 Anguiano, L., Riera, M., Pascual, J., Soler, M.J., J. Clin. Med., 4, 2015, 1171.
28. 28 Elliot, W.J., Endothelin Receptor Antagonists. Izzo, J.L., Sica, D.A., Black, H.R., (eds.) Hypertension Primer, 4th ed., 2008, Lippincott, Williams, and Wilkins, Philadelphia, 476–478.
29. 29 A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy with Atrasentan. Available at: < https://clinicaltrials.gov/ct2/show/NCT01858532?term=%22atrasentan%22+%22SONAR%22&rank=1> [Last accessed April 10, 2016].
30. 30 Murugesan, N., Gu, Z., Fadnis, L., Tellew, J.E., Baska, R.A., Yang, Y., Beyer, S.M., Monshizadegan, H., Dickinson, K.E., Valentine, M.T., Humphreys, W.G., Lan, S.J., Ewing, W.R., Carlson, K.E., Kowala, M.C., Zahler, R., Macor, J.E., J. Med. Chem., 48, 2005, 171.
31. 31 Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients with Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study. Available at: < https://clinicaltrials.gov/ct2/show/NCT01613118?term=sparsentan&rank=1> [Last accessed April 10, 2016].
32. 32 Morrison, A.R., Benabe, J.E., Taylor, A., The Role of Thromboxanes in Renal Disease. Dunn, M.J., Patrono, C., Cinotti, G.A., (eds.) Prostaglandins and the Kidney: Biochemistry, Physiology, Pharmacology, and Clinical Applications, 1983, Springer, US, Boston, 309–317.
33. 33 Nakahata, N., Pharmacol. Ther., 118, 2008, 18.
34. 34 Studer, R.K., Negrete, H., Craven, P.A., DeRubertis, F.R., Kidney Int., 48, 1995, 422.
35. 35 Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing in Two Sequential Cohorts the Safety, Efficacy and Tolerability of a 15 mg BID and a 30 mg BID Doses of SER150TBS in Well Controlled Type II Diabetic Patients with Diabetic Nephropathy and Albuminuria in Stable Antidiabetic Treatment. Available at: < https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003985-25/DE> [Last accessed April 10, 2016].
36. 36 Kolkhof, P., Nowack, C., Eitner, F., Curr. Opin. Nephrol. Hypertens., 24, 2015, 417.
37. 37 Hargovan, M., Ferro, A., Proc. R. Soc. Med. Cardiovasc. Dis., 3, 2014, 1.
38. 38 Discontinuation of Roche's RG-7641. Available at: < http://adisinsight.springer.com/drugs/800039781#disabled> [Last accessed April 13, 2016].
39. 39 McCormack, T., Arden, C., Begg, A., Caulfield, M., Griffith, K., Williams, H., Br. J. Cardiol., 20, 2013, S1.
40. 40 Kolkhof, P., Borden, S.A., Mol. Cell. Endocrinol., 350, 2012, 310.
41. 41 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care. Available at: < https://clinicaltrials.gov/ct2/show/NCT02545049?term=NCT02545049&rank=1> [Last accessed April 11, 2016].
42. 42 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease. Available at: < https://clinicaltrials.gov/ct2/show/NCT02540993?term=NCT02540993&rank=1> [Last accessed April 11, 2016].
43. 43 Liu, L.C.Y., Schutte, E., Gansevoort, R.T., van der Meer, P., Voors, A.A., Expert Opin. Investig. Drugs, 24, 2015, 1123.
44. 44 Bakris, G.L., Agarwal, R., Chan, J.C., Cooper, M.E., Gansevoort, R.T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R.E., Nowack, C., Kolkhof, P., Joseph, A., Pieper, A., Kimmeskamp-Kirschbaum, N., Ruilope, L.M., JAMA, 314, 2015, 884.
45. 45 Bramlage, P., Swift, S.L., Thoenes, M., Minguet, J., Ferrero, C., Schmieder, R.E., Eur. J. Heart Fail., 18, 2016, 28.
46. 46 A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria. Available at: < https://clinicaltrials.gov/ct2/show/NCT02345057?term=NCT02345057&rank=1> [Last accessed April 11, 2016].
47. 47 A Phase II, Randomized, Double-blind, Placebo-Controlled Study of MT-3995 in Subjects with Diabetic Nephropathy. Available at: < https://www.clinicaltrials.gov/ct2/show/NCT01889277> [Last accessed April 11, 2016].
48. 48 A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients with Diabetic Nephropathy. Available at: < https://clinicaltrials.gov/ct2/show/NCT02517320> [Last accessed: April 11, 2016].
49. 49 An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects with Mild to Moderate Renal Impairment. Available at: < https://clinicaltrials.gov/ct2/show/NCT02653014?term=KBP-5074&rank=2> [Last accessed April 11, 2016].
50. 50 Schinner, E., Wetzl, V., Schlossmann, J., Int. J. Mol. Sci., 16, 2015, 2320.
51. 51 Dousa, T.P., Kidney Int., 55, 1999, 29.
52. 52 Afsar, B., Ortiz, A., Covic, A., Gaipov, A., Esen, T., Goldsmith, D., Kanbay, M., Int. Urol. Nephrol., 47, 2015, 1521.
53. 53 Hall, R., Rowell, J., Farinelli, F., Gbadegesin, R.A., Lavin, P., Wu, G., Homstad, A., Malone, A., Lindsey, T., Jiang, R., Spurney, R., Tomaselli, G.F., Kass, D.A., Winn, M.P., Am. J. Physiol. Renal Physiol., 306, 2014, F1442.
54. 54 Whitaker, R.M., Wills, L.P., Stallons, L.J., Schnellmann, R.G., J. Pharmacol. Exp. Ther., 347, 2013, 626.
55. 55 Sabounjian, L., Graham, P., Wu, L., Braman, V., Cheng, C., Liu, J., Shipley, J., Neutel, J., Dao, M., Clin. Pharmacol. Drug Dev., 2016, 10.1002/cpdd.241/epdf Ahead of Print.
56. 56 Ghorbani, A., Omidvar, B., Beladi-Mousavi, S.-S., Lak, E., Vaziri, S., Nefrologia, 32, 2012, 790.
57. 57 Lin, S.-L., Chen, Y.-M., Chiang, W.-C., Wu, K.-D., Tsai, T.-J., Am. J. Kidney Dis., 52, 2008, 464.
58. 58 Perkins, R.M., Aboudara, M.C., Uy, A.L., Olson, S.W., Cushner, H.M., Yuan, C.M., Am. J. Kidney Dis., 53, 2008, 606.
59. 59 Navarro-González, J.F., Mora-Fernández, C., Muros de Fuentes, M., Chahin, J., Méndez, M.L., Gallego, E., Macía, M., del Castillo, N., Rivero, A., Getino, M.A., García, P., Jarque, A., García, J., Am. Soc. Nephrol., 26, 2015, 220.
60. 60 Singh, B., Diamond, S.A., Pergola, S.E., Shipley, J.E., Wu, L., Sabounjian, L.A., Graham, P.B., Am. J. Kidney Dis., 63, 2014, A1.
61. 61 Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., El Nahas, M., J. Am. Soc. Nephrol., 1, 2016, 1, 10.1681/asn.2015050473 Ahead of Print:.
62. 62 Week, Kidney, Selective Inhibition of Phosphodiesterase Type 5 Reduces Macroalbuminuria in Subjects With Type 2 Diabetes, and Overt Nephropathy. Proceedings of the Kidney Week 2014, 2014, American Society of Nephrology Annual Meeting, Philadelphia, PA, USA.
63. 63 Yu, P.H., Wright, S., Fan, E.H., Lun, Z.-R., Gubisne-Harberle, D., BBA—Proteins Proteom., 193, 2003, 1647.
64. 64 Lin, M.-S., Li, H.-Y., Wei, J.-N., Lin, C.-H., Smith, D.J., Vainio, J., Shih, S.-R., Chen, Y.-H., Lin, L.-C., Kao, H.-L., Chuang, L.-M., Chen, M.-F., Clin. Biochem., 41, 2008, 1362.
65. 65 Li, H.-Y., Jiang, Y.-D., Chang, T.-J., Wei, J.-N., Lin, M.-S., Lin, C.-H., Chiang, F.-T., Shih, S.-R., Hung, C.S., Hua, C.-H., Smith, D.J., Vanio, J., Chuang, L.-M., Diabetes, 60, 2011, 993.
66. 66 Weston, C.J., Shepherd, E.L., Claridge, L.C., Rantakari, P., Curbishley, S.M., Tomlinson, J.W., Hubscher, S.G., Reynolds, G.M., Aalto, K., Anstee, Q.M., Jalkanen, S., Salmi, M., Smith, D.J., Day, C.P., Adams, D.H., J. Clin. Invest., 125, 2015, 501.
67. 67 Schilter, H.C., Collison, A., Russo, R.C., Foot, J.S., Yow, T.T., Vieira, A.T., Tavares, L.D., Mattes, J., Teixeira, M.M., Jarolimek, W., Respir. Res., 16, 2015, 1.
68. 68 A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease. Available at: < https://clinicaltrials.gov/ct2/show/NCT02358096?term=NCT02358096&rank=1> [Last accessed: April 19, 2016].
69. 69 Seok, S.J., Lee, E.S., Kim, G.T., Hyun, M., Lee, J.H., Chen, S., Choi, R., Kim, H.M., Lee, E.Y., Chung, C.H., Nephrol. Dial. Transplant., 28, 2013, 1700.
70. 70 Awad, A.S., Kinsey, G.R., Khutsishvili, K., Gao, T., Bolton, W.K., Okusa, M.D., Am. J. Physiol. Renal Physiol., 301, 2011, F1358.
71. 71 Nam, B.Y., Paeng, J., Kim, S.H., Lee, S.H., Kim do, H., Kang, H.Y., Li, J.J., Kwak, S.J., Park, J.T., Yoo, T.H., Han, S.H., Kim, D.K., Kang, S.W., Apoptosis, 17, 2012, 1.
72. 72 Chow, F.Y., Nikolic-Paterson, D.J., Atkins, R.C., Tesch, G.H., Nephrol. Dial. Transplant., 19, 2004, 2987.
73. 73 Tesch, G.H., Am. J. Physiol. Renal Physiol., 294, 2008, F697.
74. 74 Wang, S.N., LaPage, J., Hirschberg, R., Kidney Int., 57, 2000, 1002.
75. 75 Giunti, S., Tesch, G.H., Pinach, S., Burt, D.J., Cooper, M.E., Cavollo-Perin, P., Camussi, G.G., Diabetologia, 51, 2008, 198.
76. 76 Sara, G., Federica, S., Paolo Cavallo, P., Gabriella, G., Curr. Vasc. Pharmacol., 8, 2010, 849.
77. 77 de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H.J.L., Schall, T.J., Lancet Diabetes Endocrinol., 3, 2015, 687.
78. 78 Heerspink, H.J.L., Kröpelin, T.F., Hoekman, J., de Zeeuw, D., J. Am. Soc. Nephrol., 26, 2015, 2055.
79. 79 Noxxon Website. Available at: < http://www.noxxon.com/index.php?option=com_content&view=article&id=13&Itemid=529>. [Last accessed: April 19, 2016].
80. 80 Oberthur, D., Achenbach, J., Gabdulkhakov, A., Buchner, K., Maasch, C., Falke, S., Rehders, D., Klussmann, S., Betzel, C., Nat. Commun., 6, 2015, 6923.
81. 81 A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. Available at: < https://clinicaltrials.gov/ct2/show/NCT01547897?term=NOX-E36&rank=2> [Last accessed: April 19, 2016].
82. 82 NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study. Available at: < http://www.noxxon.com/downloads/pressrel/2014-04-04_NOXXON_presents_Positive_Results_from_Emapticap_Pegol_Phase_IIa_Diabetic_Nephropathy_Study.pdf> [Last accessed: April 19, 2016].
83. 83 Wang, X., Shaw, S., Amiri, F., Eaton, D.C., Marrero, M.B., Diabetes, 51, 2002, 3505.
84. 84 Berthier, C.C., Zhang, H., Schin, M., Henger, A., Nelson, R.G., Yee, B., Boucherot, A., Neusser, M.A., Cohen, C.D., Carter-Su, C., Argetsinger, L.S., Rastaldi, M.P., Brosius, F.C., Kretzler, M., Diabetes, 58, 2009, 469.
85. 85 Zhang, H., Saha, J., Atkins, K., Brosius, F. III, J. Am. Soc. Nephrol., 23, 2012, 478A.
86. 86 Brosius, F.C. III, He, J.C., Curr. Opin. Nephrol. Hypertens., 24, 2015, 88.
87. 87 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease. Available at: < https://clinicaltrials.gov/ct2/show/NCT01683409?term=baricitinib&cond=%22Kidney+Diseases%22&rank=1> [Last accessed: April 21, 2016].
88. 88 University of Michigan Health System. Fast-tracking precision medicine: Drug re-aimed to target diabetic kidney disease. Science Daily, 10 June 2015. Available at: < www.sciencedaily.com/releases/2015/06/150610111129.htm>.
89. 89 Hayakawa, R., Hayakawa, T., Takeda, K., Ichijo, H., Proc. Jpn. Acad., Ser. B: Phys. Biol. Sci., 88, 2012, 434.
90. 90 Tobiume, K., Inage, T., Takeda, K., Enomoto, S., Miyazono, K., Ichijo, H., Biochem. Biophys. Res. Commun., 239, 1997, 905.
91. 91 Soga, M., Matsuzawa, A., Ichijo, H., Int. J. Cell. Biol., 2012, 2012, 439587.
92. 92 Tesch, G.H., Ma, F.Y., Han, Y., Liles, J.T., Breckenridge, D.G., Nikolic-Paterson, D.J., Diabetes, 64, 2015, 3903.
93. 93 Lin, J.H., Zhang, J.J., Lin, S.L., Chertow, G.M., Nephron, 129, 2015, 29.
94. 94 A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease. Available at: < https://clinicaltrials.gov/ct2/show/NCT02177786?term=GS-4997&rank=3> [Last accessed April 23, 2016].
95. 95 Gagnon, L., Leduc, M., Grouix, B., Geerts, L., Sarra-Bournet, F., Gagnon, W., Felton, A., Hince, K., Tremblay, M., Gervais, L., Cloutier, M.-P., Cesari, F., Moran, J., Laurin, P., Nephrol. Dial. Transplant., 30, 2015, iii411.
96. 96 A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome. Available at: < https://clinicaltrials.gov/ct2/show/NCT02562573?term=PBI-4050&rank=3> [Last accessed: April 25, 2016].
97. 97 Prometic Press Release, March 22, 2016. Available at: < http://www.prometic.com/prometic-confirms-pbi-4050s-positive-effects-on-novel-biomarkers-in-patients-suffering-from-metabolic-syndrome-and-type-2-diabetes/> [Last accessed: April 25, 2016].
98. 98 Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, E., Bleich, M., Grone, H.-J., Nelson, P.J., Schlondorff, D., Cohen, C.D., Kretzler, M., Diabetes, 55, 2006, 2993.
99. 99 Hodgin, J.B., Nair, V., Zhang, H., Randolph, A., Harris, R.C., Nelson, R.G., Weil, E.J., Cavalcoli, J.D., Patel, J.M., Brosius, F.C., Kretzler, M., Diabetes, 62, 2013, 299.
100. 100 Woroniecka, K.I., Park, A.S.D., Mohtat, D., Thomas, D.B., Pullman, J.M., Susztak, K., Diabetes, 60, 2011, 2354.
101. 101 Gawad, C., Koh, W., Quake, S.R., Nat. Rev. Genet., 17, 2016, 175.
102. 102 Sharma, K., Karl, B., Mathew, A.V., Gangoiti, J.A., Wassel, C.L., Saito, R., Pu, M., Sharma, S., You, Y.-H., Wang, L., Diamond-Stanic, M., Lindenmeyer, M.T., Forsblom, C., Wu, W., Ix, J.H., Ideker, T., Kopp, J.B., Nigam, S.K., Cohen, C.D., Groop, P.-H., Barshop, B.A., Natarajan, L., Nyhan, W.L., Naviaux, R.K., J. Am. Soc. Nephrol., 24, 2013, 1901.
103. 103 Kang, H.M., Ahn, S.H., Choi, P., Lo, Y.-A., Han, S.H., Chinga, F., Park, A.S.D., Tao, J., Sharma, K., Pullman, J., Bottinger, E.P., Goldberg, I.J., Susztak, K., Nat. Med., 21, 2015, 37.
104. 104 Whitaker, R.M., Wills, L.P., Stallons, L.J., Schnellmann, R.G.J., Pharacol. Exp. Ther., 347, 2013, 626.
105. 105 Boustany-Kari, C.M., Harrison, P.C., Chen, H., Lincoln, K.A., Qian, H.S., Clifford, H., Wang, H., Zhang, X., Gueneva-Boucheva, K., Bosanac, T., Wong, D., Fryer, R.M., Richman, J.G., Sarko, C., Pullen, S.S., J. Pharmacol. Exp. Ther., 356, 2016, 712.
106. 106 Dalla Vestra, M., Masiero, A., Roiter, A.M., Saller, A., Crepaldi, G., Fioretto, P., Diabetes, 52, 2003, 1031.
107. 107 Weil, E.J., Lemley, K.V., Mason, C.C., Yee, B., Jones, L.I., Blouch, K., Lovato, T., Richardson, M., Myers, B.D., Nelson, R.G., Kidney Int., 82, 2012, 1010.
108. 108 Sadowski, C.E., Lovric, S., Ashraf, S., Pabst, W.L., Gee, H.Y., Kohl, S., Engelmann, S., Vega-Warner, V., Fang, H., Halbritter, J., Somers, M.J., Tan, W., Shril, S., Fessi, I., Lifton, R.P., Bockenhauer, D., El-Desoky, S., Kari, J.A., Zenker, M., Kemper, M.J., Mueller, D., Fathy, H.M., Soliman, N.A.The SRNS Study Group, Hildebrandt, F., J. Am. Soc. Nephrol., 26, 2014, 1279.
109. 109 Schaldecker, T., Kim, S., Tarabanis, C., Tian, D., Hakroush, S., Castonguay, P., Ahn, W., Wallentin, H., Heid, H., Hopkins, C.R., Lindsley, C.W., Riccio, A., Buvall, L., Weins, A., Greka, A., J. Clin. Invest., 123, 2013, 5298.
110. 110 Winn, M.P., Conlon, P.J., Lynn, K.L., Farrington, M.K., Creazzo, T., Hawkins, A.F., Daskalakis, N., Kwan, S.Y., Ebersviller, S., Burchette, J.L., Pericak-Vance, M.A., Howell, D.N., Vance, J.M., Rosenberg, P.B., Science, 308, 2005, 1801.